Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Timing of Adjunctive Therapy in the Treatment of Depression: A Chart Review.

Tarumi R, Suzuki T, Tani H, Den R, Sawada N, Sakurai H, Tsutsumi-Ozawa C, Ohtani A, Mimura M, Uchida H.

Pharmacopsychiatry. 2014 Sep 2. [Epub ahead of print]

PMID:
25181576
[PubMed - as supplied by publisher]
2.

The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.

Thangavel C, Boopathi E, Ciment S, Liu Y, O'Neill R, Sharma A, McMahon SB, Mellert H, Addya S, Ertel A, Birbe R, Fortina P, Dicker AP, Knudsen KE, Den R.

Clin Cancer Res. 2014 Aug 27. pii: clincanres.0326.2014. [Epub ahead of print]

PMID:
25165096
[PubMed - as supplied by publisher]
3.

The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?

Blumenfeld P, Pfeffer RM, Symon Z, Den RB, Dicker AP, Raben D, Lawrence YR.

Br J Cancer. 2014 Aug 12. doi: 10.1038/bjc.2014.448. [Epub ahead of print]

PMID:
25117813
[PubMed - as supplied by publisher]
4.

Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-46. doi: 10.1016/j.ijrobp.2014.04.052. Epub 2014 Jul 8.

PMID:
25035207
[PubMed - indexed for MEDLINE]
Free Article
5.

Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.

Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Brachytherapy. 2014 Sep-Oct;13(5):456-64. doi: 10.1016/j.brachy.2014.04.003. Epub 2014 Jun 18.

PMID:
24953945
[PubMed - in process]
6.

Practical guide to the use of radium 223 dichloride.

Den RB, Doyle LA, Knudsen KE.

Can J Urol. 2014 Apr;21(2 Supp 1):70-6.

PMID:
24775727
[PubMed - in process]
Free Article
7.

A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.

Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196.

PMID:
24559451
[PubMed - in process]
8.

AR function in promoting metastatic prostate cancer.

Augello MA, Den RB, Knudsen KE.

Cancer Metastasis Rev. 2014 Sep;33(2-3):399-411. doi: 10.1007/s10555-013-9471-3.

PMID:
24425228
[PubMed - in process]
9.

Phase I trials involving radiation therapy, quantifying the risks.

Lawrence YR, Glass C, Symon Z, Dicker AP, Den RB.

J Med Imaging Radiat Oncol. 2013 Dec;57(6):719-24. doi: 10.1111/1754-9485.12082. Epub 2013 May 31.

PMID:
24283562
[PubMed - indexed for MEDLINE]
10.

High dose rate brachytherapy boost for prostate cancer: a systematic review.

Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB.

Cancer Treat Rev. 2014 Apr;40(3):414-25. doi: 10.1016/j.ctrv.2013.10.006. Epub 2013 Oct 26. Review.

PMID:
24231548
[PubMed - indexed for MEDLINE]
11.

Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.

Zaorsky NG, Den RB, Doyle LA, Dicker AP, Hurwitz MD.

Expert Rev Med Devices. 2013 Nov;10(6):751-63. doi: 10.1586/17434440.2013.841347. Review.

PMID:
24195459
[PubMed - indexed for MEDLINE]
12.

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia.

Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishii M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Okubo Y, Kato M.

Neuropsychiatr Dis Treat. 2013;9:1553-64. doi: 10.2147/NDT.S46108. Epub 2013 Oct 11.

PMID:
24143104
[PubMed]
Free PMC Article
13.

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB.

Expert Rev Anticancer Ther. 2014 Jan;14(1):39-50. doi: 10.1586/14737140.2013.836303. Review.

PMID:
24124755
[PubMed - indexed for MEDLINE]
14.

Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features: Comparative Analysis of Long-term Outcomes.

Mishra MV, Scher ED, Andrel J, Margules AC, Hegarty SE, Trabulsi EJ, Hyslop T, Den RB, Lallas CD, Gomella LG, Dicker AP, Showalter TN.

Am J Clin Oncol. 2013 Mar 26. [Epub ahead of print]

PMID:
24051934
[PubMed - as supplied by publisher]
15.

A hormone-DNA repair circuit governs the response to genotoxic insult.

Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE.

Cancer Discov. 2013 Nov;3(11):1254-71. doi: 10.1158/2159-8290.CD-13-0108. Epub 2013 Sep 11.

PMID:
24027197
[PubMed - indexed for MEDLINE]
16.

Evolution of advanced technologies in prostate cancer radiotherapy.

Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Nat Rev Urol. 2013 Oct;10(10):565-79. doi: 10.1038/nrurol.2013.185. Epub 2013 Sep 10. Review.

PMID:
24018567
[PubMed - indexed for MEDLINE]
17.

The responsibilities of a chief resident in radiation oncology: results of a national survey.

Zaorsky NG, Siglin J, Den RB, Keith SW, Showalter TN, Dicker AP, Bar-Ad V.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):460-1. doi: 10.1016/j.ijrobp.2013.06.2038. Epub 2013 Jul 29. No abstract available.

PMID:
23906932
[PubMed - indexed for MEDLINE]
18.

Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.

Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H.

Int Clin Psychopharmacol. 2013 Sep;28(5):261-6. doi: 10.1097/YIC.0b013e328363aa5a.

PMID:
23820334
[PubMed - indexed for MEDLINE]
19.

The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?

Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB.

Semin Oncol. 2013 Jun;40(3):322-36. doi: 10.1053/j.seminoncol.2013.04.011. Review.

PMID:
23806497
[PubMed - indexed for MEDLINE]
20.

Multimodality therapy for patients with high-risk prostate cancer: current status and future directions.

Zaorsky NG, Trabulsi EJ, Lin J, Den RB.

Semin Oncol. 2013 Jun;40(3):308-21. doi: 10.1053/j.seminoncol.2013.04.006. Review.

PMID:
23806496
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk